Updated: Hengrui plans China filing for obesity shot following pivotal successnews2025-07-15T11:30:39+00:00July 15th, 2025|Endpoints News|
#IAS25: WHO adds Gilead’s twice-yearly injection to global PrEP guidelinesnews2025-07-14T13:52:40+00:00July 14th, 2025|Endpoints News|
#IAS25: Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setbacknews2025-07-14T13:30:09+00:00July 14th, 2025|Endpoints News|
Takeda’s first-in-class narcolepsy drug succeeds in two registrational studiesnews2025-07-14T11:22:22+00:00July 14th, 2025|Endpoints News|
AstraZeneca blood pressure pill succeeds in pivotal trial, validating CinCor dealnews2025-07-14T11:18:46+00:00July 14th, 2025|Endpoints News|
Antag says it is confident ahead of ‘imminent’ Phase 1 obesity readout for GIP blockadenews2025-07-11T12:30:26+00:00July 11th, 2025|Endpoints News|
Century Therapeutics lays off half of its staff, CFO departs as it narrows prioritiesnews2025-07-11T11:00:33+00:00July 11th, 2025|Endpoints News|
AbbVie inks $700M deal with IGI for multiple myeloma trispecific antibodynews2025-07-10T15:30:12+00:00July 10th, 2025|Endpoints News|
Endpoints livestream: Curie.Bio CEO Zach Weinberg on China biotech competitionnews2025-07-10T11:00:20+00:00July 10th, 2025|Endpoints News|
Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummetnews2025-07-10T10:34:51+00:00July 10th, 2025|Endpoints News|
